![](https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2014/7/174318220-620x480.jpg)
Mainz Biomed seeks FDA’s Breakthrough Devices Designation for advanced colorectal cancer test
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has submitted its application to the U.S. Food and Drug Administration (FDA) requesting Breakthrough Device Designation for its non- …